Tag Archive for: licensing

disco ball party

Cologne-based DISCO Pharmaceuticals has signed a cancer drug discovery deal with AbbVie, securing $40 million (€36.5 million) upfront and potentially up to $2.5 billion (€2.3 billion) in additional payments. It is the German biotech’s second major pharma partnership this year, following its January agreement with Amgen.

china germany flags

The Swiss pharmaceutical group has agreed to another, deeper ADC partnership with China’s Hansoh Pharma, with potential milestone payments exceeding $15 billion. The deal comes amid mixed developments: While China wants to do more to protect its biotech technologies from flowing abroad, Roche’s new investment decisions in Germany are on hold for now.

drug partnering

Paris-based Enodia Therapeutics is entering a partnership with big pharma Pfizer to discover and develop small molecules for targeted protein degradation at the point of synthesis with a deal that could potentially bring more than $500 million (€446 million) to the biotech company.

crosshair reticle

Roche has partnered with China’s Defand Therapeutics to discover molecular glue degraders for cancer and immune diseases, in a research and licensing agreement reportedly worth close to $1 billion (€895 million).

Suzhou, Jiangsu, China

Novartis is paying China’s Abogen Biosciences $575 million (€512 million) upfront for global rights to ABO2203, an experimental treatment that uses mRNA to make a B-cell-depleting drug inside the patient’s body.

stack addition

GSK has selected a liver disease drug candidate from its collaboration with Wave Life Sciences for further development, triggering a $12 million (€11 million) milestone payment to the U.S.-based biotech.

alliance ring

Sanofi will pay Regeneron Pharmaceuticals $1 billion upfront (€0.9 billion) to expand the alliance that led to the blockbuster Dupixent with four antibody candidates designed to work longer between doses.

welcome aboard ship

AstraZeneca has agreed to invest $2 billion (€1.8 billion) in Summit Therapeutics and test its cancer drug ivonescimab alongside the British pharma’s antibody-drug conjugates.

gift present give back

Swiss biotech Addex Therapeutics has regained global rights to a GABA-B drug portfolio from Indivior, including a candidate for substance use disorders that has completed studies needed before a Phase 1 trial. Indivior ended the collaboration as it reorganizes R&D ahead of its proposed merger with Supernus Pharmaceuticals.

money light neon sign

Roche signed two research partnerships on Sept. 24: one with Atavistik Bio to discover drugs for cardiovascular, renal and metabolic diseases, and another with Earendil Labs to develop cancer antibodies. Together, the agreements have a potential value of more than $3.47 billion (€3.05 billion). Roche is paying $125 million (€110 million) upfront.